用于替代终点评价的双变量网络Meta分析
替代终点在监管决策中很重要,但候选替代终点常不完美,且替代终点与最终结局治疗效应的关联强度可能因治疗而异。作者开发双变量网络Meta分析方法,合并多个治疗对比试验中替代终点与最终结局的治疗效应数据,可分别估计各治疗对比的效应并建模试验水平与治疗水平的替代关系,从而预测新研究或新治疗对最终结局的效应,并用晚期结直肠癌实例和模拟研究探讨异质性与网络一致性假设的影响。
要点
- 双变量网络Meta分析可合并多治疗对比试验中替代终点与最终结局的效应数据。
- 该方法可分别估计各治疗对比的效应,并建模试验水平与治疗水平的替代模式。
- 当替代关系强度因治疗对比而异时,该方法可识别替代关系成立的治疗比较。
核心结论
- 当替代关系强度因治疗对比而异时,双变量网络Meta分析的优势在于识别替代关系成立的治疗比较,从而获得更好的预测。
研究设计与样本
- 方法学研究,开发双变量网络Meta分析方法,并用晚期结直肠癌的示例和模拟研究探讨建模假设的影响。
主要发现
- 双变量网络Meta分析可在单一分析中分别估计所有治疗对比对替代终点和最终结局的效应。
- 该方法可建模每个治疗对比内的试验水平替代模式以及治疗水平替代关系。
- 该方法可预测新人群中的新研究或新治疗对最终结局的治疗效应。
- 作者用晚期结直肠癌的示例和模拟研究探讨了关于研究间异质性和网络一致性的建模假设及其对预测的影响。
局限性
- 候选替代终点常不完美,替代终点与最终结局治疗效应之间的关联水平可能因治疗而异,这对不区分治疗的方法构成限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surrogate endpoints are very important in regulatory decision making in healthcare, in particular if they can be measured early compared to the long-term final clinical outcome and act as good predictors of clinical benefit. Bivariate meta-analysis methods can be used to evaluate surrogate endpoints and to predict the treatment effect on the final outcome from the treatment effect measured on a surrogate endpoint. However, candidate surrogate endpoints are often imperfect, and the level of association between the treatment effects on the surrogate and final outcomes may vary between treatments. This imposes a limitation on methods which do not differentiate between the treatments. We develop bivariate network meta-analysis (bvNMA) methods, which combine data on treatment effects on the surrogate and final outcomes, from trials investigating multiple treatment contrasts. The bvNMA methods estimate the effects on both outcomes for all treatment contrasts individually in a single analysis. At the same time, they allow us to model the trial-level surrogacy patterns within each treatment contrast and treatment-level surrogacy, thus enabling predictions of the treatment effect on the final outcome either for a new study in a new population or for a new treatment. Modelling assumptions about the between-studies heterogeneity and the network consistency, and their impact on predictions, are investigated using an illustrative example in advanced colorectal cancer and in a simulation study. When the strength of the surrogate relationships varies across treatment contrasts, bvNMA has the advantage of identifying treatment comparisons for which surrogacy holds, thus leading to better predictions.
引用
- Bujkiewicz S, Jackson D, Thompson JR, et al. Bivariate network meta-analysis for surrogate endpoint evaluation. Stat Med. 2019. PMID: 31131475. doi:10.1002/sim.8187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。